AVXL

3.76

1.90% +0.07

Dopo l'orario di chiusura: 3.70 -0.06 -1.60%

Anavex Life Sciences Corporation (AVXL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AVXL Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.69

Aprire:

$3.73

Volume 24 ore:

732.70K

Capitalizzazione di mercato:

$308.74M

Reddito:

Utile/perdita netta:

$-43.16M

Rapporto P/E:

-5.697

EPS:

-0.66

Flusso di cassa netto:

$-29.31M

1 W Prestazione:

+10.91%

1M Prestazione:

-17.18%

6M Prestazione:

-33.92%

1 anno Prestazione:

-53.00%

Intervallo 1D:

$3.625

$3.77

Portata 52W:

$3.25

$10.45

Anavex Life Sciences Corporation Stock (AVXL) Company Profile

Nome

Anavex Life Sciences Corporation

Settore

Healthcare (1190)

Industria

Biotechnology (681)

Telefono

844-689-3939

Indirizzo

51 West 52nd Street, 7th Floor, New York

Dipendente

Cinguettio

@anavexlifesci

Prossima data di guadagno

2024-05-09

Ultimi documenti SEC

AVXL's Discussions on Twitter

Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-12-06	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2022-06-23	Iniziato	Berenberg	Buy
2021-09-23	Iniziato	BTIG Research	Buy
2020-12-16	Reiterato	H.C. Wainwright	Buy
2020-09-28	Iniziato	Ladenburg Thalmann	Buy
2020-02-27	Iniziato	Cantor Fitzgerald	Overweight
2019-06-18	Iniziato	Janney	Buy
2018-05-16	Ripresa	Maxim Group	Buy
2018-03-08	Iniziato	ROTH Capital	Buy
2018-02-13	Reiterato	Maxim Group	Buy
2017-09-29	Ripresa	Noble Financial	Buy
2017-02-07	Iniziato	Noble Financial	Buy
2016-03-29	Iniziato	FBR Capital	Outperform

Mostra tutto

Anavex Life Sciences Corporation Borsa (AVXL) Ultime notizie

Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024

GlobeNewswire Inc.

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

GlobeNewswire Inc.

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

GlobeNewswire Inc.

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

GlobeNewswire Inc.

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

GlobeNewswire Inc.

Anavex Life Sciences Corporation Azioni (AVXL) Dati Finanziari